Galapagos signs deal with Scipher for IBD drug development
Companies will jointly validate novel IBD targets
Read More
Tag: IBD
IBD research smashes recruitment target two years early
In the UK, at least 300,000 people are affected by Crohn’s disease or ulcerative colitis.
Read More
Innovate UK grant for PredictImmune’s IBD drug response test
Innovate UK has awarded PredictImmune a £100,000 grant to apply its biomarker-based technology towards the prediction of drug response in IBD.
Read More
PredictSURE IBD gains CE mark, set for UK and EU launch
PredictImmune is gearing up to launch its novel prognostic test for inflammatory disease after it was awarded a CE mark.
Read More
SMC bars four medicines from NHS
The Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
Read More
New analysis backs use of Takeda’s Entyvio
Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.
Read More
Shire buys Pfizer’s investigational IBD biologic
Shire is buying global rights to Pfizer’s investigational biologic PF-00547659 for inflammatory bowel disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
